References
- CaroffSNMannSCNeuroleptic malignant syndromeMed Clin North Am19937711852028093494
- AddonizioGSusmanVLRothSDNeuroleptic malignant syndrome: review and analysis of 115 casesBiol Psychiatry1987228100410202886157
- CaroffSNMannSCNeuroleptic malignant syndromePsychopharmacol Bull198824125293290944
- SinghRHassanallyDNeuroleptic malignant syndrome with normal creatine kinasePostgrad Med J1996728451878731718
- NielsenJBruhnAMAtypical neuroleptic malignant syndrome caused by olanzapineActa Psychiatr Scand20051123238240 discussion 24016095481
- NisijimaKShiodaKTemporal changes in serum creatine kinase concentration and degree of muscle rigidity in 24 patients with neuroleptic malignant syndromeNeuropsychiatr Dis Treat2013985385923818785
- SachdevPSA rating scale for neuroleptic malignant syndromePsychiatry Res2005135324925615996751
- LevensonJLNeuroleptic malignant syndromeAm J Psychiatry198514210113711452863986
- PopeHGKeckPEMcElroySLFrequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospitalAm J Psychiatry198614310122712332876647
- American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders: DSM-IV-TRWashington, DCAmerican Psychiatric Association2000
- RudolfJGrondMNevelingMHeissWDCatatony in Graves’ diseaseEur Psychiatry199813841942019698658
- RosalkiSBLow serum creatine kinase activityClin Chem19984459059590359
- GranJTGunnarssonRMørkNJA man with erythrodermia, muscle weakness and weight lossTidsskr Nor Laegeforen20091292122402241 Norwegian19898573
- StrawnJRKeckPEJrCaroffSNNeuroleptic malignant syndromeAm J Psychiatry2007164687087617541044